Clinical Trial: 19064

Trial Status: Open
Trial Type: Multiple Myeloma
Disease Type: Multiple Myeloma
Trial ID 19064
Sponsor ID

A PHASE Ia/Ib OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF TIRAGOLUMAB AS A SINGLE AGENT AND IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, AND AS A SINGLE AGENT AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.(GO41036)

Principal Investigator
Gregory J. Orloff, MD

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID USOR 18126
Sponsor ID Seattle Genetics, Inc

A Phase 1 Study of SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Principal Investigator
Mitul Gandhi, MD
Trial ID USOR 20285
Sponsor ID Karyopharm Therapeutics

A Phase 2 Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor For Patients with Newly Diagnosed Multiple Myeloma

Principal Investigator
Mitul Gandhi, MD
4 Locations